Sal003 10 mg | 98.58%
TargetMol
Sal003, an effective cell-permeable analog, inhibitis the eIF2α phosphatase.
More Information Supplier PageSal003
Search Results
Sal003 25 mg | 98.58%
TargetMol
Sal003, an effective cell-permeable analog, inhibitis the eIF2α phosphatase.
More Information Supplier PageSal003
Olverembatinib dimesylate 25 mg | 99.81%
TargetMol
Olverembatinib dimesylate (GZD824 Dimesylate) is a novel orally bioavailable Bcr-Abl inhibitor for Bcr-Abl(WT) and Bcr-Abl(T315I).
More Information Supplier PageOlverembatinib dimesylate
Olverembatinib dimesylate 10 mg | 99.81%
TargetMol
Olverembatinib dimesylate (GZD824 Dimesylate) is a novel orally bioavailable Bcr-Abl inhibitor for Bcr-Abl(WT) and Bcr-Abl(T315I).
More Information Supplier PageOlverembatinib dimesylate
PHT-427 50 mg | Purity Not Available
TargetMol
PHT-427 (CS-0223) is a dual Akt (Ki: 2.7 μM) and PDPK1 (Ki: 5.2 μM) inhibitor (high-affinity binding for the PH domains of Akt and PDPK1).
More Information Supplier PagePHT-427
PHT-427 25 mg | Purity Not Available
TargetMol
PHT-427 (CS-0223) is a dual Akt (Ki: 2.7 μM) and PDPK1 (Ki: 5.2 μM) inhibitor (high-affinity binding for the PH domains of Akt and PDPK1).
More Information Supplier PagePHT-427
PHT-427 10 mg | Purity Not Available
TargetMol
PHT-427 (CS-0223) is a dual Akt (Ki: 2.7 μM) and PDPK1 (Ki: 5.2 μM) inhibitor (high-affinity binding for the PH domains of Akt and PDPK1).
More Information Supplier PagePHT-427
Sal003 5 mg | 98.58%
TargetMol
Sal003, an effective cell-permeable analog, inhibitis the eIF2α phosphatase.
More Information Supplier PageSal003
Tolvaptan 25 mg | 97.00%
TargetMol
Tolvaptan is an orally bioavailable, selective, arginine vasopressin receptor 2 (V2, AVPR2) antagonist that can be used to treat hyponatremia.
More Information Supplier PageTolvaptan
Tolvaptan 10 mg | 97.00%
TargetMol
Tolvaptan is an orally bioavailable, selective, arginine vasopressin receptor 2 (V2, AVPR2) antagonist that can be used to treat hyponatremia.
More Information Supplier PageTolvaptan